Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial
Authors' conclusion
The AHCL 780G system enhances glycemic control in children and adolescents with T1D, demonstrating improvements in HbA1c and CGM metrics, albeit most participants did not achieve optimal glycemic control.
Study context
- Population
- Children and adolescents with T1D in their initial 12 months of MiniMed 780G use; 43% girls, median age 15.1 years (IQR 12.9,17.0)
- Participants
- 93 children
- Exposure
- MiniMed 780G Advanced Hybrid Closed-Loop (AHCL) use: 12 months vs baseline
- 780Gn = 93
- Outcome
- Longitudinal changes in glycemic parameters and composite optimal glycemic control measures (CGC, GRI, COGI scores) and their predictors
- Follow-up
- 12 months
Methodological detailsmulticenter, single-group, real-life
- Multicenter
- Single-group
- Real-life
Main finding
As reported in the abstract
HbA1c · baseline to 1 year
Mean hemoglobin A1c (HbA1c) (SE) at baseline
8.65%
0.12
Mean HbA1c (SE) after 1 year (dropped by >1%)
7.54%
0.14
Change over time in HbA1c
ptime < 0.001
Significant improvement in glycemic control, adjusted for age and socioeconomic index
ptime < 0.001
Observational data: associations, not effects.
Further findings
Optimal glycemic control measures · 12 months
- Composite glycemic control (CGC) improved 5.6-fold (P < 0.001)
- 24% attained
- Glycemia risk index (GRI) improved 10-fold (P = 0.009)
- 10% achieved
- COGI improved 7.6-fold (P < 0.001)
- 20% attained
Predictors of optimal glycemic control
- Lower baseline HbA1c and greater adherence to AHCL use predicted optimal glycemic control
Original publication
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial. Diabetes Technol Ther. Published 31 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →